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Patients with severe left ventricular (LV) dysfunction, isch-emic heart failure, and coronary artery disease (CAD) 
suitable to coronary artery bypass grafting (CABG) benefit 
from CABG.1 Because these patients are at higher risk of 
surgical morbidity and mortality than patients with milder 
forms of LV dysfunction, clinicians remain hesitant to refer 
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from CABG are also at the greatest operative risk, which makes decision making regarding whether to proceed to surgery 
difficult in such patients. To better inform such decision making, we analyzed the Surgical Treatment for Ischemic Heart 
Failure (STICH) CABG population for detailed information on perioperative risk and outcomes.
Methods and Results—In both STICH trials (hypotheses), 2136 patients with a left ventricular ejection fraction of ≤35% and 
coronary artery disease were allocated to medical therapy, CABG plus medical therapy, or CABG with surgical ventricular 
reconstruction. Relationships of baseline characteristics and operative conduct with morbidity and mortality at 30 days 
were evaluated. There were a total of 1460 patients randomized to and receiving surgery, and 346 (≈25%) of these high-risk 
patients developed a severe complication within 30 days. Worsening renal insufficiency, cardiac arrest with cardiopulmonary 
resuscitation, and ventricular arrhythmias were the most frequent complications and those most commonly associated with 
death. Mortality at 30 days was 5.1% and was generally preceded by a serious complication (65 of 74 deaths). Left ventricular 
size, renal dysfunction, advanced age, and atrial fibrillation/flutter were significant preoperative predictors of mortality 
within 30 days. Cardiopulmonary bypass time was the only independent surgical variable predictive of 30-day mortality.
Conclusions—CABG can be performed with relatively low 30-day mortality in patients with left ventricular dysfunction. 
Serious postoperative complications occurred in nearly 1 in 4 patients and were associated with mortality.
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these patients for CABG. Paradoxically, there is evidence that 
higher-risk patients with LV dysfunction and CAD, such as 
those with a lower LV ejection fraction (LVEF), more LV dila-
tation, and multivessel disease benefit the most from CABG.2 
Thus, physicians and patients are left with challenging deci-
sions. Will the potential benefits for a given individual out-
weigh the short- and long-term morbidity and mortality of the 
procedure? A number of well-accepted surgical risk scores 
exist to help guide clinicians and patients in making informed 
decisions regarding the risks of surgery.3–6 However, although 
helpful, these scores have not been specifically devised for 
patients with severe LV dysfunction (LVEF≤35%).
The Surgical Treatment for Ischemic Heart Failure 
(STICH) trial evaluated the role of CABG versus medical 
treatment and of CABG versus CABG plus surgical ventric-
ular reconstruction (SVR) in patients with CAD amenable 
to CABG and a LVEF≤35%.7 In addition to providing infor-
mation regarding the risk of early (within 30 days) postop-
erative mortality, STICH provides information on the risk of 
postoperative complications and their impact on outcomes. 
Once surgery has been successfully performed and the first 
critical postoperative period survived, little information 
exists to inform the healthcare team regarding the progno-
sis of an individual patient or the impact of complications 
on their postoperative course.8 The STICH trial provides 
an opportunity to evaluate clinical and surgical character-
istics that identify patients at risk for both early and late 
postoperative morbidity and mortality, information that can 
help influence decisions on how to proceed given a specific 
patient profile.
The objectives of the present analyses were to (1) evaluate 
the association of baseline patient characteristics and operative 
conduct on 30-day postoperative complications and mortality 
and (2) evaluate the incidence of postoperative complications 
and their association with 30-day mortality.
Methods
The overall objective of the STICH trial was to define the role of 
revascularization surgery in the management of patients with isch-
emic cardiomyopathy. STICH tested 2 hypotheses: (1) whether 
CABG is superior to optimal medical treatment alone in improv-
ing survival in patients with a LVEF≤35% and CAD amenable to 
CABG, and (2) whether the addition of SVR to CABG in patients 
with anterior wall akinesis or dyskinesis is superior to CABG alone. 
The STICH trial hypothesis 1 results found that, although CABG 
did not significantly reduce all-cause mortality in comparison with 
optimal medical therapy alone, it did reduce the combined prespeci-
fied secondary end point of all-cause mortality plus cardiovascular 
hospitalization.9 The results of hypothesis 2 found that the addition 
of SVR to CABG alone did not improve mortality or freedom from 
cardiovascular hospitalization.10
The STICH trial was carefully planned to create a unique cohort 
of international CABG-eligible patients with CAD and a LVEF≤35% 
for whom preoperative, intraoperative, and postoperative data were 
prospectively acquired by using structured data forms with stan-
dardized descriptions of common operative and postoperative treat-
ment decisions. Past performance of at least 25 CABG operations 
on patients with a LVEF of ≤0.40 with an operative mortality of 
≤5% was required for certification of all STICH surgeons. STICH 
cardiologists and cardiac anesthesiologists experienced in managing 
operative and perioperative care of CABG patients helped coordi-
nate preoperative and postoperative patient management decisions. 
All participating cardiac surgeons composed the STICH Surgical 
Committee that met regularly during the active recruitment and treat-
ment phase of the study.7
The Duke University Medical Center Institutional Review Board 
and the institutional review board or ethics committee for each par-
ticipating institution approved the study protocol, and all the patients 
provided written informed consent.
Patient Population
Between July 24, 2002, and May 5, 2007, 2136 patients were enrolled 
in the National Institutes of Health–funded STICH trial11 and ran-
domly assigned to treatment with medical therapy alone (n=602), 
medical therapy plus CABG (n=1033), and medical therapy plus 
CABG and SVR (n=501; Figure 1). Of 1534 STICH patients ran-
domly assigned to surgery, 74 did not undergo surgery (11 patients 
died after randomization and before surgery). Among the 1460 
patients who received CABG, there were 495 patients who under-
went CABG with SVR and 965 patients who underwent CABG 
alone. Patients randomly assigned to medical therapy that ultimately 
received CABG during the follow-up period (n=65) were not consid-
ered for these analyses because detailed perioperative and postopera-
tive data were not collected in these patients.
All patients randomly assigned in STICH underwent base-
line evaluations that included imaging of the LV at randomization. 
Descriptions of operative conduct and occurrence of perioperative 
complication events were recorded on the structured surgical treat-
ment clinical report form by using explicit definitions (see online-
only Data Supplement), and recorded at the time of hospital discharge 
post-CABG or at 30 days for patients who remained in the hospi-
tal for ≥30 days. Follow-up clinical assessment was performed at 
the time of hospital discharge or at 30 days post operation, and at 
4-month intervals for the first year of follow-up, and thereafter at 
6-month intervals over the remainder of the follow-up period. All 
postoperative in-hospital morbid events and complications that met a 
prespecified definition (online-only Data Supplement) and occurred 
within 30 days after the operation were tabulated.
The following postoperative complications were documented and 
considered major: return to the operating room (OR) for bleeding; 
return to the OR for any reason; mediastinitis; pulmonary edema 
requiring intubation; new-onset ventricular arrhythmia; cardiac arrest 
requiring cardiopulmonary resuscitation; worsening renal insuffi-
ciency (increase >2 mg/dL or 2× baseline creatinine or both); gas-
trointestinal complications; respiratory compromise; other major 
complications; acute myocardial infarction; and stroke. The follow-
ing postoperative complications were documented and considered 
Patients allocation in both 
STICH Trials 
N=2136
CABG + MED
N=1033
CABG + MED + SVR
N=501
Randomized to 
Surgical Therapy 
N=1534
Received Operation
Assigned by Randomization 
N=1460
673 (46%) CABG on pump
393 (27%) CABG/SVR
160 (11%) CABG off pump
132 (9%) CABG/MVR
102 (7%) CABG/SVR/MVR
Did Not Undergo 
Surgical Treatment
N=74
Medical Therapy
N=602
Patients who
crossed over to 
surgery 
did not have 
intraoperative and 
postoperative events 
documented in the 
surgical CRF (n=65)
Figure 1. Consort diagram of patients enrolled in STICH that 
had CABG and the type of surgery performed. CABG indicates 
coronary artery bypass grafting; CRF, Case Report Form; MED, 
medical therapy; MVR, mitral valve repair/replacement; STICH, 
Surgical Treatment for Ischemic Heart Failure; and SVR, surgical 
ventricular reconstruction.
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nonmajor: infection other than mediastinitis, new-onset atrial fibril-
lation, and delirium.
Statistical Analyses
Patient and operative conduct characteristics were summarized as 
number (percentage) for categorical variables and as median (25th, 
75th percentile) for continuous variables. The characteristics of 
patients who did and did not develop major complications and who 
did and did not die within 30 days were summarized and compared 
with χ2, Fisher’s exact, or Wilcoxon rank-sum tests. Mortality rates 
in patients with different complications within the early postopera-
tive interval are presented as Kaplan-Meier rates at 30 days. The Cox 
proportional hazards regression model was used in both univariable 
and multivariable analyses to identify baseline and perioperative fac-
tors associated with 30-day mortality. Time to death was censored at 
30 days post operation in these analyses. The multivariable analysis 
used a backward elimination procedure to determine independently 
significant prognostic factors. For continuous variables, if needed, 
appropriate restricted cubic spline functions were used to assess lin-
earity of the relationship of predictors with the log-hazard ratio in the 
Cox model. Candidate variables included baseline and intraoperative 
conduct characteristics. P values of <0.05 were considered statisti-
cally significant. All analyses were performed with SAS version 9.2 
(SAS Institute, Inc, Cary, NC).
Results
Patient Outcomes
Of the 1460 patients who underwent CABG, 74 patients 
(5.1%) died within 30 days after surgery (of whom 65 [88%] 
died following at least 1 major complication). Five patients 
died in the OR, 45 died in an intensive care unit, 15 died in 
the step-down unit, and 9 died at home or in another facility. A 
total of 346 patients (23.7%) experienced at least 1 major com-
plication. Of these 346 patients with at least 1 major complica-
tion, 65 (18.8%) died within 30 days of surgery. The remaining 
1105 (75.7%) patients were alive without major complications 
at 30 days post operation. Patients without a major compli-
cation had <1% mortality, those with 1 major complication 
(14.3%) had 7% mortality, those with 2 major complica-
tions (5.8%) had 31% mortality, those with 3 major complica-
tions (1.6%) had 33% mortality, and those having ≥4 major 
complications (2.0%) had 59% mortality at 30 days.
Serious Postoperative Complications
The characteristics of patients who developed a serious post-
operative complication in comparison with patients without 
serious complications are shown in Table 1. At enrollment, 
patients with postoperative complications were older, had 
more renal dysfunction defined as creatinine >1.5 mg/dL, pre-
vious CABG, more severe angina (Canadian Cardiovascular 
Society class), more symptomatic heart failure (New York 
Heart Association class), a higher Duke CAD score, more 
atrial fibrillation or flutter, a lower LVEF, a lower hemoglobin, 
and a lower 6-minute walk. Surgical characteristics of patients 
developing postoperative complications included prolonged 
aortic cross-clamp time, prolonged cardiopulmonary bypass 
pump time, and less use of cardioplegia. Surgical charac-
teristics that marginally increased the risk of postoperative 
complications included SVR or mitral valve surgery. Notable 
characteristics not significantly associated with postoperative 
complications included diabetes mellitus, LV end-systolic 
volume index (LVESVI), and number of distal anastomoses.
The most frequent postoperative complications (Table 2) 
were worsening renal insufficiency (8.4%), new-onset ventric-
ular arrhythmias (7.1%), cardiac arrest requiring cardiopulmo-
nary resuscitation (4.7%), return to the OR for bleeding (3.8%), 
return to the OR for other reasons (3.6%), and pulmonary 
edema requiring intubation (3.1%). The complications most 
frequently associated with death were renal insufficiency (37 
deaths), cardiac arrest requiring cardiopulmonary resuscita-
tion (35 deaths), new-onset ventricular arrhythmia (31 deaths), 
and pulmonary edema requiring intubation (18 deaths). Acute 
myocardial infarction was infrequent (0.8%) but resulted in a 
high death rate (42%). Stroke was also infrequent (1.6%) and 
was not associated with as great a risk (17%) as most other 
major complications. Finally, the incidence of mediastinitis 
was low (1.7%) and associated with a relatively low mortality 
rate (8%) in comparison with other major complications.
Early (30 Days) Postoperative Mortality
The baseline preoperative characteristics of patients who died 
within 30 days post operation differed in a number of respects 
in comparison with those who survived (Table 3). Patients who 
died were older and had renal dysfunction, atrial fibrillation or 
flutter, more symptomatic heart failure, more mitral regurgita-
tion, a lower LVEF, and a lower hemoglobin. In addition, they 
had a greater LVESVI and more peripheral vascular disease. 
Differences between the groups in less frequently occurring 
characteristics such as a history of stroke (12.2% versus 6.3%) 
did not reach statistical significance. The only operative char-
acteristic associated with 30-day mortality was bypass time. 
Type of cardioplegia was not associated with mortality.
Univariable Relationship of Baseline and Surgical 
Characteristics (Conduct) With Mortality at 30 Days
The univariable relationships that were strongly predictive 
of 30-day mortality (Table 4) were creatinine, age, LVESVI, 
New York Heart Association class, hemoglobin, the presence 
of baseline atrial fibrillation or flutter, previous CABG, and 
bypass pump time >120 minutes.
Multivariable Model of Baseline and Operative 
Conduct and 30-Day Mortality
The multivariable model (C statistic of 0.83) identified creati-
nine and LVESVI as the 2 most powerful baseline and opera-
tive conduct characteristics for predicting 30-day mortality 
(Table 5). Mortality risk increased linearly with creatinine 
>1 mg∕dL and appeared to level off at 1.6 mg∕dL (Figure 2), 
although the number of patients with more elevated creati-
nine values was limited. Other strong (P<0.01) characteristics 
identified included age and moderate or severe mitral regur-
gitation. Other predictive characteristics were current angina, 
atrial fibrillation or flutter, hemoglobin, the preoperative use 
of both statins and aspirin, clopidogrel, or warfarin (reduced 
risk), cardiopulmonary bypass time >120 minutes, mitral 
valve procedure (reduced risk), body mass index, peripheral 
vascular disease, and a high Duke CAD index.
Discussion
This is the largest international cohort of CABG-eligible 
patients with CAD and low LVEF (≤35%) for whom 
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Table 1. Baseline and Surgical Characteristics and Complications
n No Major Complications n One or More Major Complications P Value*
Age at randomization 1114 60.2 (53.3, 67.5) 346 65.1 (57.5, 71.3) <0.0001
Female 1114 148 (13.3) 346 52 (15.0) 0.4100
Myocardial infarction 1114 918 (82.4) 346 294 (85.0) 0.2670
Hyperlipidemia 1111 756 (68.0) 346 229 (66.2) 0.5181
Hypertension 1114 645 (57.9) 346 224 (64.7) 0.0236
Diabetes mellitus 1114 397 (35.6) 346 137 (39.6) 0.1818
Peripheral vascular disease 1114 156 (14.0) 346 59 (17.1) 0.1622
Chronic renal insufficiency 1113 57 (5.1) 346 61 (17.6) <0.0001
Body mass index, kg/m2 1114 27.0 (24.4, 30.1) 346 27.2 (23.9, 30.5) 0.8051
Creatinine, mg/dL 1114 1.05 (0.90, 1.20) 346 1.16 (1.00, 1.40) <0.0001
Hemoglobin, g/dL 1114 13.8 (12.7, 14.9) 346 13.6 (12.4, 14.7) 0.0127
Stroke 1114 66 (5.9) 346 31 (9.0) 0.0477
Previous PCI 1114 174 (15.6) 346 68 (19.7) 0.0780
Previous CABG 1114 22 (2.0) 346 16 (4.6) 0.0069
Current Canadian Cardiovascular Society Angina 
Class
1114 346 0.0073
  None 313 (28.1) 108 (31.2)
  I 113 (10.1) 31 (9.0)
  II 317 (28.5) 70 (20.2)
  III 313 (28.1) 107 (30.9)
  IV 58 (5.2) 30 (8.7)
Current NYHA heart failure class 1114 346 <0.0001
  I 111 (10.0) 25 (7.2)
  II 546 (49.0) 131 (37.9)
  III 420 (37.7) 160 (46.2)
  IV 37 (3.3) 30 (8.7)
Number of diseased vessels (≥75% stenosis) 1114 346 0.0650
  None 24 (2.2) 5 (1.4)
  One 223 (20.0) 55 (15.9)
  Two 454 (40.8) 132 (38.2)
  Three 413 (37.1) 154 (44.5)
Left main stenosis ≥50% 1114 147 (13.2) 346 58 (16.8) 0.0952
Proximal LAD stenosis ≥75% 1113 805 (72.3) 346 253 (73.1) 0.7725
Duke CAD index (0–100) 1114 65 (39, 77) 346 65 (43, 91) 0.0078
LVEF 1114 28 (23, 34) 346 26 (22, 33) 0.0068
LVESVI 1114 78 (59, 97) 346 81 (61, 104) 0.0705
Distance walked at baseline, meters 835 357 (280, 420) 234 331 (240, 399) 0.0005
Atrial fibrillation/flutter 1114 112 (10.1) 346 58 (16.8) 0.0007
Statin and at least 1 of ASA, clopidogrel, or warfarin 1114 768 (68.9) 346 217 (62.7) 0.0309
Mitral regurgitation 1111 340 0.0679
  None or trace 417 (37.5) 110 (32.4)
  Mild (≤2+) 515 (46.4) 162 (47.6)
  Moderate (3+) 150 (13.5) 51 (15.0)
  Severe (4+) 29 (2.6) 17 (5.0)
Number of distal anastomoses 1111 3 (2, 4) 343 3 (2, 4) 0.4778
Number of distal anastomoses, n (%) 1111 343 0.4504
  0–1 101 (9.1) 32 (9.3)
  2–3 685 (61.7) 199 (58.0)
  ≥4 325 (29.3) 112 (32.7)
(Continued )
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preoperative, intraoperative, and postoperative data were 
prospectively acquired permitting the analysis of variables 
associated with 30-day postoperative mortality and morbidity. 
Major postoperative complications were relatively frequent 
(23.7% of all cases) and correlated with death in 88% of fatal 
cases. Not surprisingly, clinical and operative characteristics 
predictive of postoperative complication and 30-day mortal-
ity were similar, with 1 notable exception. Increased LVESVI 
was not significantly associated with the risk of postopera-
tive complications, but was 1 of the 2 characteristics most 
predictive of 30-day mortality. The only operative conduct 
characteristic predictive of 30-day mortality was prolonged 
cardiopulmonary bypass time, which likely reflects a more 
difficult or complicated operative procedure.12–14
Postoperative Complications
When a complication occurred, it was frequently followed by 
at least another complication (137 of 346 patients), and mor-
tality increased markedly as more complications occurred.15 
Preoperative renal dysfunction, indices of LV dysfunction 
More distal anastomoses than conduits 1114 258 (23.2) 346 78 (22.5) 0.8119
Arterial conduits ≥1, n (%) 1114 1019 (91.5) 346 308 (89.0) 0.1657
On pump surgery 1114 983 (88.2) 346 317 (91.6) 0.0789
Mitral valve procedure 1114 164 (14.7) 346 70 (20.2) 0.0147
SVR procedure 1114 362 (32.5) 346 133 (38.4) 0.0413
Surgery was not elective 1114 130 (11.7) 346 51 (14.7) 0.1301
Cardioplegia 1110 346 0.0039
  None 177 (15.9) 41 (11.8)
  Crystalloid 254 (22.9) 62 (17.9)
  Blood 646 (58.2) 223 (64.5)
  Both 33 (3.0) 20 (5.8)
Bypass pump time, min 1114 95 (65, 127) 346 112 (75, 158) <0.0001
Cardiopulmonary bypass time >120 min 1114 321 (28.8) 346 151 (43.6) <0.0001
Aorta cross-clamp time, min 1114 58 (36, 83) 346 67 (41, 95) 0.0001
The entries in this table are median (25th, 75th percentiles) for continuous variables and n (%) for categorical variables. ASA indicates aspirin; CABG, coronary artery 
bypass grafting; CAD, coronary artery disease; LAD, left anterior descending; LVEF, left ventricular ejection fraction; LVESVI, left ventricular end-systolic volume index; 
NYHA, New York Heart Association; PCI, percutaneous coronary intervention; and SVR, surgical ventricular reconstruction.
*Wilcoxon rank-sum tests used for continuous variables and χ2 tests used for categorical variables.
Table 2. Perioperative Complications
Complications n (%) Deaths
30-day Kaplan-Meier 
Mortality Rate, %
Major complication
  Worsening renal insufficiency  
(increase >2 mg/dL and 2× baseline creatinine)
123 (8.4) 37 30
  Cardiac arrest requiring CPR 69 (4.7) 35 51
  New-onset ventricular arrhythmia 103 (7.1) 31 30
  Pulmonary edema requiring intubation 45 (3.1) 18 40
  Other major complication 21 (1.4) 9 43
  Return to OR for other reason 53 (3.6) 9 17
  Return to OR for bleeding 56 (3.8) 7 12
  Acute MI 12 (0.8) 5 42
  Stroke 24 (1.6) 4 17
  Respiratory compromise 31 (2.1) 4 13
  GI complication 14 (1.0) 2 14
  Mediastinitis 25 (1.7) 2 8
Complications not considered major
  New-onset atrial fibrillation/flutter 329 (22.5) 26 8
  Other infection 132 (9.0) 13 10
  Delirium 65 (4.5) 7 11
CPR indicates cardiopulmonary resuscitation; GI, gastrointestinal; MI, myocardial infarction; and OR, operating room. 
Table 1. Continued
n No Major Complications n One or More Major Complications P Value*
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Table 3. Baseline and Surgical Characteristics and 30-Day Mortality
n Alive at 30 Days n 30-Day Death P Value*
Age at randomization 1386 60.8 (53.9, 68.1) 74 66.1 (59.9, 71.7) 0.0002
Female 1386 190 (13.7) 74 10 (13.5) 0.9621
Myocardial infarction 1386 1146 (82.7) 74 66 (89.2) 0.1465
Hyperlipidemia 1383 941 (68.0) 74 44 (59.5) 0.1244
Hypertension 1386 817 (58.9) 74 52 (70.3) 0.0532
Diabetes mellitus 1386 502 (36.2) 74 32 (43.2) 0.2216
Peripheral vascular disease 1386 194 (14.0) 74 21 (28.4) 0.0007
Chronic renal insufficiency 1385 102 (7.4) 74 16 (21.6) <0.0001
Body mass index, kg/m2 1386 27.0 (24.3, 30.1) 74 27.3 (23.4, 30.5) 0.9595
Creatinine, mg/dL 1386 1.08 (0.92, 1.24) 74 1.30 (1.05, 1.50) <0.0001
Hemoglobin, g/dL 1386 13.8 (12.7, 14.9) 74 13.1 (12.2, 14.6) 0.0369
Stroke 1386 88 (6.3) 74 9 (12.2) 0.0869
Previous PCI 1386 231 (16.7) 74 11 (14.9) 0.6847
Previous CABG 1386 31 (2.2) 74 7 (9.5) 0.0023
Current Canadian Cardiovascular Society 
Angina Class
1386 74 0.0302
  None 406 (29.3) 15 (20.3)
  I 139 (10.0) 5 (6.8)
  II 368 (26.6) 19 (25.7)
  III 395 (28.5) 25 (33.8)
  IV 78 (5.6) 10 (13.5)
Current NYHA heart failure class 1386 74 0.0001
  I 134 (9.7) 2 (2.7)
  II 647 (46.7) 30 (40.5)
  III 549 (39.6) 31 (41.9)
  IV 56 (4.0) 11 (14.9)
Number of diseased vessels (≥75% 
stenosis)
1386 74 0.1796
  None 29 (2.1) 0 (0)
  One 269 (19.4) 9 (12.2)
  Two 550 (39.7) 36 (48.6)
  Three 538 (38.8) 29 (39.2)
Left main stenosis ≥50% 1386 194 (14.0) 74 11 (14.9) 0.8342
Proximal LAD stenosis ≥75% 1385 996 (71.9) 74 62 (83.8) 0.0258
Duke CAD Index (0–100) 1386 65 (39, 77) 74 65 (52, 91) 0.0312
LVEF 1386 28 (23, 34) 74 25 (20, 30) 0.0002
LVESVI 1386 78 (59, 98) 74 94 (71, 110) <0.0001
Distance walked at baseline, meters 1022 350 (274, 420) 47 310 (224, 450) 0.3178
Atrial fibrillation/flutter 1386 151 (10.9) 74 19 (25.7) 0.0001
Statin and at least one ASA, clopidogrel, 
or warfarin
1386 945 (68.2) 74 40 (54.1) 0.0115
Mitral regurgitation 1378 73 0.0004
  None or trace 513 (37.2) 14 (19.2)
  Mild (≤2+) 639 (46.4) 38 (52.1)
  Moderate (3+) 187 (13.6) 14 (19.2)
  Severe (4+) 39 (2.8) 7 (9.6)
Total number of distal anastomoses 1381 3 (2, 4) 73 3 (2, 4) 0.6633
Number of distal anastomoses, n (%) 1381 73 0.5555
  0–1 124 (9.0) 9 (12.3)
  2–3 843 (61.0) 41 (56.2)
  ≥4 414 (30.0) 23 (31.5)
(Continued )
 by guest on M
arch 15, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
726  Circulation  August 25, 2015
including LVEF, and exertional tolerance, such as New York 
Heart Association class and distance walked, were the patient 
characteristics most closely associated with the development 
of major postoperative complications. Although it would 
appear that particular caution should be exercised when con-
sidering CABG in these patients, these are precisely the clini-
cal characteristics that identify those patients who may have 
the most to gain from CABG.2 Strategies to optimize pre- and 
perioperative renal16 and cardiac function as well as myocar-
dial protection17–19 may be particularly important factors to 
consider in the management of these complex patients.20
Postoperative 30-Day Mortality
Worsening renal function (37 of 74 deaths), cardiac arrest 
requiring cardiopulmonary resuscitation (35 of 74 deaths), 
the development of ventricular arrhythmias (31 of 74 deaths), 
and pulmonary edema requiring intubation (18 of 74 deaths), 
were the postoperative complications most frequently associ-
ated with death. Worsening renal function probably reflects 
numerous risk factors and probably also contributes to the 
development of pulmonary edema requiring intubation. These 
complications are all generally associated with poor or wors-
ening LV function, which may also be reflective of a compli-
cated, difficult, and prolonged operation.
Myocardial infarction, stroke, and mediastinitis were rea-
sonably infrequent and associated with a relatively small num-
ber of deaths, 5, 4, and 2, respectively. The low major adverse 
event rate of these 3 complications may help explain the low 
30-day postoperative mortality seen in the STICH trial.21
Patients undergoing CABG with impaired LV function 
are among the most challenging patients undergoing coronary 
surgery.22 Commonly, the EuroSCORE, Society of Thoracic 
Surgeons, and New York state risk scores are used to assess 
the risk in patients undergoing CABG.3–6 These risk scores do 
not specifically and thoroughly address the patient with severe 
LV dysfunction. However, as with commonly used risk scores, 
STICH identified advanced age, renal dysfunction, low LVEF, 
and the presence of more advanced atherosclerosis, whether a 
higher Duke CAD severity score or the presence of peripheral 
vascular disease, as important risk factors. Again, although 
Duke CAD severity score identified patients at higher risk, 
previous analyses of STICH have also identified these patients 
to be among those that benefit most by CABG.2 As opposed to 
commonly used risk scores, sex was not predictive of 30-day 
mortality in STICH.
The second most powerful predictor of 30-day mortal-
ity in STICH was LVESVI. Mortality risk increased linearly 
with increasing values of LVESVI (Figure 2). This measure-
ment not only reflects reduced LVEF, but reflects the degree 
of LV remodeling that is itself an independent predictor of 
poor outcome.23 Well-established surgical risk scores have 
identified LVEF as a very powerful predictor of surgical 
and 30-day mortality, but, because of the lack of availabil-
ity, LVESVI has not been included in these scores. In STICH 
patients, LVESVI was a stronger predictor of 30-day mortality 
than LVEF as a significant independent predictor of 30-day 
mortality. Postinfarct studies have also found LVESVI to be 
a more important predictor of outcome than LVEF.24 Thus, 
in considering the surgical risk of death in patients with LV 
dysfunction, LVESVI should be carefully evaluated because 
it appears to carry more prognostic significance for risk than 
does LVEF and also predicts a better outcome with CABG 
than with medical therapy alone.2
The only operative conduct characteristic predictive of 
30-day mortality was prolonged cardiopulmonary bypass 
time. As mitral valve surgery was associated with reduced 
mortality, and SVR was not independently associated with 
increased mortality, it would appear likely that the increased 
More distal anastomoses than conduits 1386 323 (23.3) 74 13 (17.6) 0.2533
Arterial conduits ≥1, n (%) 1386 1264 (91.2) 74 63 (85.1) 0.0774
On pump surgery 1386 1231 (88.8) 74 69 (93.2) 0.2350
Mitral valve procedure 1386 219 (15.8) 74 15 (20.3) 0.3072
SVR procedure 1386 466 (33.6) 74 29 (39.2) 0.3243
Surgery was not elective 1386 170 (12.3) 74 11 (14.9) 0.5086
Cardioplegia 1382 74 0.7758
  None 204 (14.8) 14 (18.9)
  Crystalloid 301 (21.8) 15 (20.3)
  Blood 826 (59.8) 43 (58.1)
  Both 51 (3.7) 2 (2.7)
Bypass pump time, min 1386 97 (66, 131) 74 125 (90, 176) <0.0001
Cardiopulmonary bypass time >120 min 1386 434 (31.3) 74 38 (51.4) 0.0003
Aorta cross-clamp time, min 1386 60 (37, 86) 74 72 (32, 92) 0.1413
The entries in this table are median (25th, 75th percentiles) for continuous variables and n (%) for categorical variables. ASA indicates aspirin; CABG, coronary artery 
bypass grafting; CAD, coronary artery disease; LAD, left anterior descending; LVEF, left ventricular ejection fraction; LVESVI, left ventricular end-systolic volume index; 
NYHA, New York Heart Association; PCI, percutaneous coronary intervention; and SVR, surgical ventricular reconstruction.
*Fisher’s exact tests used for stroke and previous CABG. χ2 tests used for the remaining categorical variables, and Wilcoxon rank-sum tests used for continuous 
variables.
Table 3. Continued
n Alive at 30 Days n 30-Day Death P Value*
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Table 4. Univariable Association Between Baseline and Surgical Characteristics and 30-Day Mortality
Characteristic HR (95% CI) χ2 P Value
Age, HR for 10-y increase 1.60 (1.25–2.05) 13.63 0.0002
Female 0.99 (0.51–1.93) <0.01 0.9732
Myocardial infarction 1.71 (0.82–3.56) 2.06 0.1512
Hyperlipidemia 0.70 (0.44–1.11) 2.36 0.1244
Hypertension 1.61 (0.98–2.66) 3.55 0.0597
Diabetes mellitus 1.33 (0.84–2.11) 1.48 0.2233
Peripheral vascular disease 2.35 (1.42–3.90) 10.99 0.0009
Chronic renal insufficiency 3.22 (1.85–5.60) 17.14 <0.0001
BMI, HR for 1 kg/m2 increase 10.39 0.0155
  ≤ 25 0.83 (0.74–0.93)
  25–30 1.19 (1.02–1.37)
Creatinine, HR for 0.1 mg/dL increase 35.94 <0.0001
  ≤1.0 0.68 (0.52–0.89)
  1.0–1.4 1.65 (1.38–1.97)
Hemoglobin, HR for 1 g/dL increase 13.11 0.0044
  <12.5 1.21 (0.82–1.78)
  12.5–15.5 0.64 (0.48–0.84)
  >15.5 2.08 (1.32–3.29)
Stroke 2.00 (1.00–4.02) 3.80 0.0511
Previous PCI 0.87 (0.46–1.66) 0.17 0.6774
Previous CABG 4.16 (1.91–9.07) 12.89 0.0003
Current angina 1.62 (0.92–2.85) 2.75 0.0971
Current NYHA HF class, HR for 1 category increase 1.80 (1.30–2.49) 12.73 0.0004
Number of diseased vessels (≥75% stenosis) 1.21 (0.90–1.63) 1.54 0.2153
Left main stenosis ≥ 50% 1.07 (0.56–2.03) 0.04 0.8412
Proximal LAD stenosis ≥ 75% 1.99 (1.07–3.69) 4.76 0.0292
Duke CAD Index, HR for 10 U increase 7.88 0.0194
  ≤ 53 1.81 (1.16–2.82)
  > 53 0.95 (0.80–1.14)
Ejection fraction, HR for 10% increase 0.58 (0.44–0.77) 14.11 0.0002
ESVI, HR for 100 mL/m2 increase 3.19 (1.90–5.34) 19.34 <0.0001
Atrial fibrillation/flutter 2.70 (1.60–4.55) 13.92 0.0002
Statin and at least one ASA, clopidogrel, or warfarin 0.56 (0.36–0.89) 6.13 0.0133
Moderate or severe mitral regurgitation 1.99 (1.20–3.31) 7.17 0.0074
Total number of distal anastomoses 1.01 (0.82–1.25) 0.01 0.9036
More distal anastomoses than conduits 0.71 (0.39–1.29) 1.29 0.2569
Arterial conduits ≥ 1 0.56 (0.30–1.07) 3.11 0.0777
CABG with CPB 1.71 (0.69–4.25) 1.35 0.2450
Mitral valve procedure 1.34 (0.76–2.36) 1.03 0.3111
SVR procedure 1.26 (0.79–2.02) 0.97 0.3250
Surgery was not elective 1.24 (0.65–2.35) 0.43 0.5142
Cardioplegia (reference is none) 1.12 0.7730
  Crystalloid 0.73 (0.35–1.52)
  Blood 0.76 (0.42–1.39)
  Both 0.58 (0.13–2.55)
Cardiopulmonary bypass time > 120 min 2.27 (1.44–3.58) 12.38 0.0004
ASA indicates aspirin; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CI, confidence interval; CPB, cardiopulmonary 
bypass; LAD, left anterior descending; ESVI, end-systolic volume index; HF, heart failure; HR, hazard ratio; NYHA, New York Heart 
Association; PCI, percutaneous coronary intervention; and SVR, surgical ventricular reconstruction.
 by guest on M
arch 15, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
728  Circulation  August 25, 2015
risk associated with cardiopulmonary bypass time is reflective 
of a more difficult and complex revascularization procedure 
rather than concomitant surgical procedures. Consistent with 
this hypothesis is the lack of association between mortality 
and aortic cross-clamp time found in this and other analyses.12
Mitral valve surgery at the time of CABG was the only 
surgical characteristic associated with improved 30-day sur-
vival. It is unclear why this was associated with improved 
survival, but it may result from a beneficial effect on patients 
with significant mitral regurgitation and heart failure.25,26 In 
STICH, mitral valve repair (221 of 234 mitral valve surger-
ies) was the overwhelming form of mitral valve surgery per-
formed, such that differential results for mitral valve repair 
versus replacement cannot be evaluated. The finding of 
reduced risk with mitral valve surgery in the present analysis 
is also consistent with the long-term benefits demonstrated in 
STICH when mitral valve repair is performed at the time of 
CABG in patients with moderate to severe mitral regurgita-
tion.27 These findings also differ from those of a recent trial of 
300 patients with moderate ischemic mitral regurgitation ran-
domly assigned to receive CABG plus mitral repair or CABG 
only.28 In those patients, who had significantly better LV func-
tion than in STICH, no significant difference was found in 
LVESVI, survival, or quality of life at 12 months, but there 
was a 30% lower prevalence of moderate or severe mitral 
regurgitation, suggesting that mitral valve repair may have 
greater benefit in patients with more severe LV dysfunction, 
or that the benefit of mitral valve repair may not be seen until 
these patients have been followed for a longer period of time.
Clinical Implications
This analysis of the STICH trial data has identified a num-
ber of patient characteristics that predict an increased risk 
of 30-day postoperative complications and mortality risk. 
Paradoxically some of these risk factors, such as LVESVI, 
LVEF, and more extensive CAD, also predict which patients 
will improve most with CABG. The presence of moderate to 
severe mitral regurgitation also predicts patients at greater 
risk, but again, mitral regurgitation repair appears to have a 
marked beneficial effect, both short and long term and should 
be performed when appropriate. Other factors that increase 
risk and that are difficult to modify, such as renal dysfunction, 
advanced age, and the presence of atrial fibrillation or flut-
ter, among others, may encourage surgeons to perhaps choose 
operative procedures that limit cardiopulmonary bypass time.
Limitations
The results of these analyses need to be viewed within the 
context of the STICH trial where these procedures were per-
formed by surgical teams with proven excellent results in 
such high-risk patients. Also, patients in STICH were rela-
tively young (with a median age of 61 years) when enrolled 
and mortality may be higher than that reported in STICH for 
older more fragile patients and those with other comorbidi-
ties. Finally, this STICH analysis did not consider patients 
that crossed over from medical therapy to CABG. Although 
the addition of these 65 patients may have altered the results 
somewhat because these crossover patients had a particularly 
Table 5. Multivariable Association Between Baseline 
and Surgical Characteristics and 30-Day Mortality (C 
statistic=0.826)
Variable HR (95% CI) P Value
Creatinine, HR for 0.1 mg/dL increase <0.0001
  ≤1.0 0.67 (0.51–0.89)
  1.0–1.4 1.52 (1.26–1.82)
ESVI, HR for 100 mL/m2 increase 2.73 (1.50–4.98) 0.0010
Age, HR for 10-y increase 1.47 (1.12–1.93) 0.0052
Moderate or severe mitral regurgitation 2.35 (1.27–4.34) 0.0065
Current angina 2.08 (1.17–3.70) 0.0126
Atrial fibrillation/flutter 1.97 (1.14–3.39) 0.0153
Hemoglobin, HR for 1 g/dL increase 0.0178
  <12.5 1.41 (0.91–2.19)
  12.5–15.5 0.68 (0.51–0.90)
  >15.5 1.88 (1.19–2.96)
Cardiopulmonary bypass time >120 min 1.83 (1.10–3.04) 0.0199
Body mass index, HR for 1 kg/m2 increase 0.0202
  0–25 0.86 (0.76–0.97)
  25–30 1.21 (1.04–1.41)
Mitral valve procedure 0.43 (0.20–0.90) 0.0251
Peripheral vascular disease 1.84 (1.07–3.18) 0.0278
Statin and at least 1 ASA, clopidogrel, or 
warfarin
0.58 (0.36–0.95) 0.0285
Duke CAD Index, HR for 10-point increase 
to 53
1.46 (1.00–2.13) 0.0485
ASA indicates aspirin; CAD, coronary artery disease; CI, confidence interval; 
ESVI, end-systolic volume index; and HR, hazard ratio.
Figure 2. Relationship between creatinine and LVESVI vs 30-day 
mortality and the 95% confidence interval (dotted lines). LVESVI 
indicates left ventricular end-systolic volume index.
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good outcome,29 it is probable that their inclusion would have 
had limited impact on our findings.
These analyses identified patient and operative character-
istics associated with increased risk of serious postoperative 
complications and mortality, but did not evaluate interventions 
that could reduce these risks. Also, other variables known to 
be important in assessing postoperative risk, such as pulmo-
nary hypertension, that were not prospectively collected and 
not considered in these analyses may be as important in iden-
tifying risk as those considered in the present analyses.
Conclusions
The STICH trial demonstrated that CABG can be performed 
with relatively low 30-day mortality in patients with severe 
LV dysfunction and ischemic heart failure. Despite this low 
mortality, serious complications are relatively common in 
these high-risk patients and occur before death in the major-
ity of patients dying within 30 days of surgery. Greater renal 
dysfunction, LVESVI, advanced age, and preoperative atrial 
fibrillation or flutter are the strongest baseline characteristics 
predictive of a poor survival. Prolonged cardiopulmonary 
bypass time is the single operative characteristic indepen-
dently predictive of poor early outcome.
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SUPPLEMENTAL MATERIAL 
 
Supplemental Methods:  CRF instructions to sites for patients randomized to CABG or 
CABG + SVR treatment 
 
Mediastinitis: Any wound disruption exposing the sternum or requiring a secondary operation 
or stabilization of the sternum prior to discharge. 
 
Other infection: All other types of major postoperative infections (except mediastinitis), such 
as pneumonia, pyelonephritis, septicemia, and infections at the vein-harvest site. 
 
New onset atrial flutter/fibrillation (AF): New onset AF in a patient that was previously in 
normal sinus rhythm (regardless of history of AF) at randomization lasting at least 24 hours 
and/or requiring electrical or chemical cardioversion. 
 
New onset ventricular arrhythmia: Ventricular tachycardia sustained for >30 seconds or 
ventricular tachycardia requiring anti-arrhythmic or cardioversion. 
 
Worsening renal insufficiency: An insufficiency resulting in an increase of >2 mg/dL and 2x 
baseline creatinine level or a new requirement for dialysis. 
 
Delirium: State of mental confusion and excitement characterized by disorientation for time 
and place, usually with illusions and hallucinations. 
 
Acute MI: A myocardial infarction characterized by at least 2 of the following criteria: 
 Prolonged (>20 min) typical chest pain not relieved by rest and/or nitrates. 
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 Enzyme level elevation defined as troponin T or I ≥3x ULN or CK-MB ≥2x normal in 
medically treated patients, CK-MB ≥3x normal in patients after PCI, or CK-MB ≥5x 
normal in patients after CABG. 
 At least 2 serial ECGs with changes and/or serially in ST-T and/or Q waves that are 
0.03 seconds in width and/or one third or more of the total QRS complex in 2 or more 
contiguous leads. 
Stroke: A new central neurological deficit (i.e., extremity weakness or loss of motion, loss of 
consciousness, loss of speech, field cuts) of sudden onset that is not reversible within 24 
hours and not due to a readily identifiable cause (i.e. brain tumor, or trauma) persisting >72 
hours after onset or leading to death.  
 
Complications, which were available to check by investigators in the clinical report 
form, had pre-specified definitions, but also an open category "other." All 
complications filled in category "other" are listed in Supplemental Table 1. After 
reviewing this list based on clinical judgment, two authors/investigators, who are 
experienced cardiac surgeons, made the decision to create new categories: GI 
complications, respiratory compromise, other major, and other non-major. 
 
Supplemental Table 1 
All postoperative in-hospital morbid events and complications that met a pre-specified 
definition that occurred within 30 days after operation were tabulated.  Definitions follow. 
Major Complications Derived from Case Report Form (CRF) Text 
Gastrointestinal 
Peripheral, abdominal embolism (suspected) 
Small bowel ischemia 
Acute pancreatitis 
GI bleeding 
Cholestasis 
Ileus 
Upper GI bleed 
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Hospitalized for GI distress 
Gastric bleeding 
Mesenteric ischemia 
GI bleeding duodenal 
Lower digestive tract hemorrhage 
Acute gastritis 
 
Respiratory compromise 
 Respiratory insufficiency 
 Left bronchus obturation requiring bronchoscopy and aspiration 
 Intensive respiratory therapy 
 Tracheostomy  
 Pneumothorax  
 Pneumothorax [left pleural effusion] 
 Respiratory distress 
 Pneumonia with reintubation 
 Desaturation to below 90% oxygen saturation on room air 
 Respiratory arrest 
 Pneumothorax 
 Re-intubation 
 Tracheotomy 
 Reintubation for bronchospasm 
 Reintubation for low oxygen saturation 
 Respiratory failure 
 Pneumonia with intubation 
 Intubation 
 Nitric oxide inhalation (patient died at ICU being intubated) 
 Pleural effusion 
 Reintubation for chronic obstructive pulmonary disease 
 
Other major complications 
 Defibrillation 
 Pulmonary embolus 
 Tamponade 
 Multi-organ failure (MOF) 
 Severe bleeding 
 ECMO 
 Cardiogenic shock 
 Heart failure 
 Right femoral thrombectomy Grade IV medical limits 
 Low cardiac output – heart failure 
 Hypotension traced back to ACU 
 Sepsis 
 Seizures 
 Liver failure 
 Systemic inflammatory response syndrome 
 Septic shock 
 ECMO 
 Stroke 
 Dialysis 
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Not considered major and not included as a complication in the models 
 Left pleural effusion 
 Large left pleural effusion 
 Pleural effusion 
 Pleural effusion 
 Pleural effusion and puncture 
 Electrocardioversion 
 IABP placed electively at preinduction of anesthesia 
 IABP 
 Pneumocystydiosis 
 Recurrent atrial fibrillation 
 Anemia, requested 3 blood units 
 Postoperative anemia requiring transfusion 
 Anemia, requested 2 blood transfusion 
 2 units of PRBCS and 1 unit of FFP 
 Blood transfusion 
 Oliguria 
 Intraventricular conduction delay 
 Cardioversion for atrial flutter/fibrillation 
 Hyperamylasemia 
 Perianal abscess 
 Leg edema 
 Ventricular fibrillation/cardiac arrest before enrollment to STICH 
 Psychotic syndrome 
 Hydrothorax 
 Pneumonia 
 Pericardial fluid 
 Thoracentesis 
 Unstable sternum 
 Hypotension 
 Anaphylactic reaction postoperatively 
 Hematuria 
 Depression 
 RFA radiofrequency ablation was performed because of macro re-entry atrial tachycardia 
 Low output syndrome 
 Coagulopathy 
 Anterior compartment syndrome of left lower extremity requiring fasciotomy and muscle 
debridement 
 Hemodynamic instability at the time of chest opening (beginning of the procedure) resulted in low 
cardiac output of the wheezing from cardiopulmonary bypass at the end of the procedure 
 Allergic reaction against plasma transfusion 
 Transient ischemic attack 
 Transient ischemic attack 
 Pericardial effusion syndrome post cardiotomy 
 Transient sinus pause 
 Hyperthermia 
 Chronic renal insufficiency 
 Cerebrovascular accident – stroke or TIA  
 Hyperkalemia 
 Hyperamylasemia 
 Tinnitis 
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 Low hematocrit 
 Left ventricular thrombus 
 Peripheral artery occlusion 
 Fever 
 Arrhythmia 
 High chest tube output 
 Temporary pacemaker for heart rate 
 Non-functioning ICD re-implant 
 
 
